Phacilitate Vaccine Forum Spring 2005 - May 23-25, 2005 - Amsterdam
Phacilitate Vaccine Forum Spring 2005
May 23-25, 2005 - Amsterdam
The Grand Hotel Krasnapolsky
The Spring 2005 event - the seventh Phacilitate Vaccine Forum - provides you with the perfect opportunity to raise your profile and network with many of the industry?s senior level corporate and R&D decision makers. This will be the third time that the event returns to Amsterdam - the exclusive, yet informal, atmosphere of The Grand Hotel Krasnapolsky is highly conducive to fruitful discussions, with all attendees making the most of their time away from day-to-day pressures to take a fresh look at solutions to common strategic challenges. Indeed, the meeting has quickly gained a reputation for the quantity and quality of interactions, and is widely recognised as the premier partnering event for the vaccines community in Europe today.
Over 80% of participants in Phacilitate Vaccine Forums are at Director level and above, reflecting the profile of the speaker panel. In addition, the events consistently attract a higher proportion of delegates from companies actively involved in vaccine R&D than any other in the marketplace. Senior management from all stages of the R&D pipeline are represented, as well as the Heads of R&D themselves and senior members of corporate management from both biotech companies and 'the big 5'.
Speakers:
Dr John Shiver Vice President, Vaccine & Biologics Research, Merck Research Laboratories
Daniel J. Carucci, MD, PhD Director, Grand Challenges in Global Health Initiative
Dr Thomas Fuerst Director, Vaccines & Biologics, Office of Public Health Emergency Preparedness, US Department of Health & Human Services
Dr Allan P. Jarvis Senior Vice President, Corporate Development, Sanofi Pasteur
Dr Hartmut Ehrlich Vice President, Global Clinical Research & Development, Baxter BioScience
Dr David Salisbury CB Principal Medical Officer, UK Department of Health
Dr William Gruber Vice President, Clinical Research, Wyeth Vaccines
Dr John P. Hennessey Senior Director, Bioprocess & Bioanalytical Research, Merck Research Laboratories
Dr Klaus St?hr Team Coordinator, WHO Global Influenza Programme, World Health Organisation
Dr Guiseppe Del Giudice Vice President, Serology & Animal Models, Chiron Vaccines
Jan Reid Director of Licensing, Wyeth Vaccines
Peter Welford Biotechnology Analyst, Merrill Lynch Europe
Dr Marie-Th?r?se Martin Head of HPV Vaccine Late Development, GlaxoSmithKline Biologicals
Dr Michael Pfleiderer Head of Viral Vaccines Section, Paul-Ehrlich-Institut
Dr Luc Hessel Executive Director, Medical & Public Affairs, Europe, Aventis Pasteur MSD & Chairman, The Influenza Vaccine Supply International Task Force
Dr Steve Chatfield CSO, Emergent BioSolutions, Inc
Dr Dennis Foley Vice President, Vaccine Regulatory Affairs, Wyeth Vaccines
Paul Kirkconnell Sanofi-Aventis Capital
Dr Robert Sitrin Executive Director, Bioprocess & Bioanalytical Research, Merck Research Laboratories
Dr William Egan Executive Director, PharmaNet Consulting
Dr Marion Gruber Scientific Reviewer, Microbiologist, CBER, FDA
Dr Peter Khoury Vice President, Global Marketing, Vaccines, Baxter BioSciences
Dr Beatrice De Vos Director, Worldwide Medical Support, GlaxoSmithKline Biologics
Drs Jill Dekker-Bellamy New Defence Agenda
Dr Henrik S. Rasmussen Senior Vice President, Clinical Research, Medical & Regulatory Affairs & Project Management, Nabi Biopharmaceuticals
Dr David Fedson Formerly, Harry T. Peters, Jr. Professor of Internal Medicine,University of Virginia School of Medicine, & formerly Director of Medical Affairs, Europe, Aventis Pasteur MSD
Dr Jack Love Assistant Vice President, World Wide Regulatory Affairs, Wyeth Vaccines
Dr William M. Egan Executive Director, PharmaNet Consulting
Professor Ben van der Zeijst Scientific Director, Netherlands Vaccine Institute
Dr Brigitte Keller-Stanislawski Member of the EMEA Pharmacovigilance Working Party, Head of Pharmacovigilance, Paul-Ehrlich-Institut
Dr Ronald W. Ellis Senior Vice President, Development, & General Manager, ID Biomedical Corporation of Northborough
Dr Katharina Hartmann Head of Pharmacovigilance, Berna Biotech
Una S. Ryan, PhD, OBE President & CEO, AVANT Immunotherapeutics, Inc
Dr Lydia Falk Director, Office of Regulatory Affairs, National Institute of Allergy & Infectious Diseases (NIAID)
Dr Kathleen Coelingh Senior Director, Regulatory & Scientific Affairs, MedImmune Vaccines, Inc
Dr Rudolf Schosser Medical Director, Baxter Germany
Fran?ois Thomas Partner, Atlas Venture
Renald Hennig MD MBA Executive Director Pharmacovigilance, Chiron Vaccines
Dr Jeremy Reffin Director, Apax Partners
Dr Stephen Lockhart Senior Director, Head of Bacterial Vaccine Clinical Research, Wyeth Vaccines Research
David L. Urdal, PhD Chief Scientific Officer, Dendreon
Dr Lance K. Gordon CEO, VaxGen
Dr Erich Tauber Head of Product Development & Medical Affairs, Intercell AG
Mark Leuchtenberger President and CEO, Therion Biologics Corporation
A. C. G. Voordouw, MD, MPH Senior Clinical Assessor, Medicines Evaluation Board
Dr Johan van Hoof
Brian Kerr Investment Director, Scottish Equity Partners
Professor Angus Dalgleish Research Director, Onyvax Limited
Dr Alexander von Gabain CEO, Intercell AG
Dr Thomas Steinbach Qualified Person for European Pharmacovigilance, Wyeth Research
Patricia A. Cleveland, PhD Regulatory Consultant, Vaccine and Biological Product Development
Professor Adrian V.S. Hill Wellcome Trust Principal Research Fellow, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford
Dr Paul Chaplin Vice President & CSO, Bavarian Nordic
Lee Holmes Business Development Manager, Xenova
Votes:15
Comments: 0